Sozinibercept
drugOn this page
Also known as Opt-302OPT302VGX-300VGX300
Summary
Sozinibercept (CHEMBL5095152) is a phase-3 clinical-stage protein; indicated across 3 conditions including age-related macular degeneration and macular degeneration.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Indications: 3 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5095152 |
| Name | Sozinibercept |
| Type | Protein |
| Max phase | 3 |
Also known as: Opt-302, OPT-302, OPT302, Sozinibercept, VGX-300, VGX300, SOZINIBERCEPT
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| age-related macular degeneration | 3 | MONDO:0005150 | EFO:0001365 |
| macular degeneration | 3 | MONDO:0003004 | EFO:0009606 |
| retinal disorder | 1 | MONDO:0005283 | HP:0000479 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE2 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04757610 | PHASE3 | TERMINATED | OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) |
| NCT04757636 | PHASE3 | TERMINATED | OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) |
| NCT03345082 | PHASE2 | COMPLETED | A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD |
| NCT03397264 | PHASE1/PHASE2 | COMPLETED | A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema |
| NCT02543229 | PHASE1 | COMPLETED | Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).